Calcitonin gene-related peptide (CGRP) is a potent vasodilator neuropeptide known to be involved in the regulation of vascular resistance. Several lines of evidence suggest that CGRP plays a role in the vascular adaptations that occur during normal pregnancy; however, the effects of exogenous CGRP on systemic and regional hemodynamics during pregnancy remain unknown. Therefore, the purpose of this study was to determine the hemodynamic effects of systemically administered CGRP in adult pregnant (Day 19) and ovariectomized (ovx) rats using the radioactive microsphere technique. In addition, we also used ovariectomized rats treated for 3 days with estradiol (E 2 ), progesterone (P 4 ), E 2 ؉ P 4 in sesame oil, or oil only to assess if these hormones regulate the CGRP-induced hemodynamic changes. On the day of study, catheters were inserted into the left cardiac ventricle (through the right carotid artery), right jugular vein, and caudal tail artery. Hemodynamic studies using radioactive microspheres were then performed in conscious rats 3 h after recovery from anesthesia. Blood pressure and heart rate were continuously monitored, and left ventricular pressure was determined immediately prior to each microsphere injection. Microspheres labeled with either 141 Ce or 85 Sr were injected prior to and 2 min following the i.v. bolus injection of CGRP (270 pmol/kg body weight [BW]). Mean arterial pressure (MAP) and total vascular resistance in pregnant rats was lower than in ovx rats, and this was further decreased with an i.v. bolus injection of 270 pmol CGRP/kg BW. Cardiac output was elevated with further increases upon CGRP administration in pregnant but not in ovx rats. The CGRP-induced changes in MAP, total vascular resistance, and cardiac output in E 2 ؉ P 4 -treated rats were similar to that observed in Day 19 pregnant rats, indicating that CGRP effects on these parameters during pregnancy may be modulated by steroid hormones. Both pregnancy and E 2 ؉ P 4 treatment in ovx rats caused significant decreases in CGRP-induced resistance in mesenteric, coronary, and renal vasculature. Thus, the vasodilatory sensitivity to CGRP during pregnancy may be mediated through decreased total vascular resistance, particularly to coronary, mesenteric, and renal vascular beds. Thus, CGRP-induced vasodilatory effects may play a role in mediating vascular adaptations that occur during pregnancy and that steroid hormones may modulate these CGRP effects.
INTRODUCTION
Normal pregnancy in humans and animals is characterized by an increase in cardiac output, blood volume, heart rate, and a decrease in arterial blood pressure due to a significant reduction in total peripheral resistance in order to provide a suitable environment for embryo/fetal development. Any abnormal alterations of these hemodynamic adaptations to pregnancy may cause hypertension leading to impaired fetal growth and increased fetal mortality rate. The mechanism(s) responsible for maintaining the decreased vascular resistance during pregnancy is still unknown. Reports indicate that several locally produced vasoactive agents could contribute to the physiological changes that occur during pregnancy. These include nitric oxide (NO) [1] , prostacyclin [2] , and calcitonin gene-related peptide (CGRP) [3] [4] [5] [6] .
CGRP, a 37-amino acid neuropeptide, has been identified in multiple species, including rat and man [7] [8] [9] . A dense perivascular CGRP neural network is seen around the blood vessels in virtually all vascular beds [10, 11] , the uterus [12] , and ovary in rats [13] . In vivo and in vitro studies have demonstrated that CGRP is approximately 100 times more potent as a vasodilator than acetylcholine and substance P. CGRP dilates rat aortic rings in vitro [14] and systemic administration of CGRP decreases blood pressure (BP) in a dose-dependent manner [15] . The primary mechanism responsible for this BP reduction is peripheral arterial dilation. Furthermore, CGRP increases blood flows to various organs in male rats with maximal increases observed in the coronary circulation [16] . In addition to its vasodilator properties, CGRP has been shown to have potent chronotropic and inotropic effects [17] . These data indicate that CGRP participates in the regulation of systemic and regional hemodynamics by virtue of its potent vasodilator activity.
Recent studies from our laboratory have demonstrated that female sex steroid hormones stimulate CGRP mRNA expression and peptide synthesis in dorsal root ganglia neurons [18] . Plasma immunoreactive CGRP (i-CGRP) concentrations were increased during pregnancy and decreased at the time of delivery and postpartum in humans and rats [19] [20] [21] . In addition, i-CGRP levels in serum of nonpregnant ovariectomized (ovx) rats were significantly increased with estradiol (E 2 ) and progesterone (P 4 ) treatments [21] . Thus, increases in the synthesis of CGRP might play an important role in maintaining normal systemic and regional hemodynamics during pregnancy.
We have recently reported that CGRP lowers the blood pressure and fetal mortality induced by the nitric oxide inhibitor N G -nitro-L-arginine methyl ester (L-NAME) during pregnancy in rats [6] , and this effect appeared to be P 4 dependent [4] . Furthermore, other studies indicate that CGRP plays a compensatory vasodilator role to attenuate the elevated blood pressure in L-NAME-treated pregnant rats, [3] . These reports suggest that CGRP has a beneficial role in maintaining the normal physiological adaptations that occur during pregnancy.
Therefore, the present study was undertaken to examine the effects of exogenous CGRP on systemic and regional hemodynamics in conscious, unrestrained pregnant rats and ovx controls to determine whether the vasodilator properties of CGRP are enhanced during pregnancy. Because pregnancy is a state when serum E 2 and P 4 are elevated and that these steroid hormones are shown to modulate both CGRP synthesis and CGRP effects on vasodilation in nonpregnant rats, we also examined the effects of exogenous CGRP on systemic and regional hemodynamics in ovx rats treated with steroid hormones.
MATERIALS AND METHODS

Animal Care, Handling, and Treatments
Time-mated pregnant (Day 1, i.e., day of positive sperm smear) and nonpregnant (170-200 g body weight [BW]) rats were purchased from Harlan Sprague-Dawley (Houston, TX) and housed in a temperature-controlled (22ЊC) environment with a 12L:12D cycle. All animals were fed standard rat chow with water to drink ad libitum. All procedures were approved by the Animal Care and Use Committee of the University of Texas Medical Branch. A group of four to six time-mated pregnant rats, on Day 19 of gestation and ovx nonpregnant rats (200 g BW) were used in this study. Nonpregnant animals were bilaterally ovariectomized under general anesthesia using ketamine (Fort Dodge Laboratories, Fort Dodge, IA; 45 mg/kg BW) and xylazine (Burns Veterinary Supply, New York, NY; 5 mg/ kg BW). Seven days after the surgery, groups of ovx rats received one of the four different treatments: 1) E 2 (2.5 g per injection, twice daily for 3 days in 0.2 ml sesame oil); 2) P 4 (2 mg per injection, twice daily for 3 days in 0.2 ml sesame oil); 3) combination of E 2 and P 4 (2.5 g E 2 and 2 mg P 4 per injection, twice daily for 3 days in 0.2 ml sesame oil); or 4) vehicle (sesame oil) (Sigma Chemical Co., St. Louis, MO). All treatments were given subcutaneously. Hemodynamic measurements and blood flow determinations were made in all these animals using previously published procedures [15, 16, 22] .
Surgical Procedure for Catheterization
On the morning of the study, rats were weighed and then anesthetized with ketamine and xylazine as described above. A midline ventral incision was made through the skin at the base of the tail to expose ventral caudal artery. A catheter consisting of 22 cm of polyethylene tubing (PE-50) was advanced 1.5 cm into the vessel and secured. An incision was made at the dorsal base of the tail, and catheter was passed subcutaneously for exteriorization at the nape of the neck. To protect the exposed catheter, a 4-cm length of plastic tube was placed over the tail/catheter and secured with monofilament surgical steel at the base of the tail. Dorsal and ventral tail incisions were coated with 2% lidocaine paste, prior to the tube placement.
A midventral incision was made in the neck to expose the right carotid artery. A catheter (PE-50) consisting of 30 cm length was inserted into the right carotid artery and advanced 4-5 cm into the left cardiac ventricle. Placement of the catheter tip in the left ventricle was confirmed by the left ventricular pressure pulse tracing and the exact position was verified at autopsy. The catheter was secured and then tunneled subcutaneously and exteriorized at the nape of the neck adjacent to the caudal artery catheter. Another catheter (PE-50) of 30 cm length was inserted into the left jugular vein and secured and exteriorized at the nape of the neck. Then the ventral incision was closed, and a purse-string suture was placed around the dorsal incision and tied. All incision sites were coated with 2% lidocaine paste.
Catheters were flushed and filled with heparin saline and plugged. Animals were placed in individual cages to recover from anesthesia/surgery for at least 3 h. Food and water were provided ad libitum during recovery.
Blood pressure and heart rates were continuously monitored and left ventricular pressures were determined immediately before each radioactive microsphere injection (DBP001 direct blood pressure system; Kent Scientific Corporation, Litchfield, CT). The acute experiments were begun following attainment of a stable baseline BP and heart rate.
Blood Flow Measurements
Systemic and regional hemodynamics were determined by the radioactive microsphere technique as previously described [22, 23] . The radioactive microspheres (15.5 Ϯ 0.1 m in diameter from Dupont/NEN, Boston, MA) were obtained as a stock solution in a suspending vehicle of normal saline with 0.05% polysorbate 80 (Tween 80) added. Prior to use, the vials containing the spheres were sonicated for 10-15 min to ensure a well-mixed suspension and to eliminate clumping of spheres. Each rat received a 20-sec intraventricular injection of 0.3 ml (approximately 250 000 spheres) of microspheres labeled with either 141 cerium or 85 strontium followed by a 0.5-ml saline flush over a 20-to 30-sec period. Fifteen seconds prior to microsphere injection, reference blood sample withdrawal was begun from the caudal artery at a rate of 0.4 ml/min and continued for a total of 1.5 min. Where indicated, a second microsphere injection with the alternate isotope was performed. At the end of each experiment, the animals were deeply anesthetized with ketamine/xylazine via the cannulated jugular vein, and killed by decapitation. Desired tissue/organ samples were surgically removed from all animals, blotted to remove excess moisture, and weighed. Additionally, in pregnant rats, the placentas were carefully removed from the uterus and separated from amniotic membranes and fluid, blotted dry, and weighed. The left ventricle was examined for evidence of catheter-induced trauma and if such trauma was noted, the data from that rat were discarded. Tissue samples, arterial reference samples, and microsphere suspension standards were counted for radioactivity. Systemic and regional hemodynamics were then calculated according to previously described standard equations [22] . Microsphere tracer injected into the ventricle of rats has previously been shown to provide adequate mixing to allow accurate determination of blood flow in organs distal to the injection site.
Nevertheless, in the present studies paired left-right tissue flow values differing by Յ10% from the mean of paired samples were required to indicate acceptable experimental conditions. In addition, we have initially assessed the repeatability of the preparation by using 141 cerium-and 85 strontium-labeled microspheres in that sequence or in the reverse sequence and after injection of saline in place of CGRP. Data confirmed that these preparations were repeatable (data not shown). 
Hemodynamic Measurements
Total injected activity for each isotope was estimated by determining the activity of triplicate injection volumes of microsphere suspension divided into multiple tubes, as described by Flaim et al. [23] . Cardiac output, tissue distribution of blood flow, and total and regional organ vascular resistance were calculated from radioactive microsphere data, according to the following equations [22] : cardiac output ϭ [cpm injected ϫ arterial reference flow (ml/min)]/ cpm in arterial reference; organ blood flow (ml min Ϫ1 g Ϫ1 ) ϭ [cpm in organ (g) ϫ arterial reference flow (ml/min)]/ cpm in arterial reference; total vascular resistance (mmHg ml Ϫ1 min Ϫ1 ) ϭ [mean arterial pressure (mmHg)]/[cardiac output (ml/min)]; organ vascular resistance (mmHg ml
.
Experimental Protocol
The hemodynamic measurements and microsphere injection for each animal were conducted in pregnant animals on Day 19 and in ovx rats treated with steroid hormones, under control resting conditions in their postoperative recovery cages. A second hemodynamic measurement and injection of microsphere with second radioactive label were conducted 2 min after administration of a bolus dose of CGRP (270 pmol/kg BW) through jugular vein catheter. The dose of CGRP and the 2-min time point was chosen based on our prior studies [5] . In these studies, maximum vasodilatory responses occurred at 2 min after bolus i.v. injection of CGRP at 180-360 pmol/kg BW.
Statistics
All data are expressed as the mean Ϯ SEM. Differences between groups were determined by one-way ANOVA followed by the Bonferroni t-test. Paired t-test was utilized for changes in various parameters upon CGRP administration within each group. A P value of less than 0.05 was considered significant.
RESULTS
Effects of CGRP on Systemic Hemodynamics in Pregnant and Nonpregnant Rats
Mean arterial pressure (MAP), cardiac output, and total vascular resistance in pregnant rats on Day 19 of gestation and in ovx nonpregnant rats before and after bolus administration of CGRP (270 pmol/kg BW) are presented in Figure 1 . The MAP in pregnant rats (85 Ϯ 4.6 mmHg) was significantly (P Ͻ 0.05) lower than that in ovx animals (101 Ϯ 5 mmHg) (Fig. 1A) . Injection of CGRP into pregnant rats caused a significant (P Ͻ 0.05) further reduction in MAP (68 Ϯ 3.8 mmHg) but not in ovx rats. The cardiac output (ml/min) was elevated during pregnancy (157 Ϯ 5) compared with ovx rats (125 Ϯ 4) (Fig. 1B) . CGRP administration induced a significant increase in cardiac output in pregnant (199 Ϯ 10.0) but not in ovx (145 Ϯ 5.4) rats. The total vascular resistance (mmHg ml Ϫ1 min Ϫ1 ) in preg- nant animals (0.62 Ϯ 0.05) was significantly lower compared to ovx (0.72 Ϯ 0.08) rats (Fig. 1C) . Systemic administration of CGRP further reduced the vascular resistance, which was significant (P Ͻ 0.05) in the pregnant (0.38 Ϯ 0.03) but not in ovx (0.65 Ϯ 0.05) rats.
Effects of CGRP on the Regional Vascular Resistance and Blood Flows
The effects of CGRP on the regional organ vascular resistance and blood flows in both pregnant and ovx rats are shown in Tables 1 and 2 , respectively. We measured the vascular resistance and blood flows to various organs in both pregnant and ovx rats and assessed the changes in these parameters in response to CGRP. Because pregnancy is also a state of reduced vascular resistance, we initially compared the pregnancy-related changes in vascular resistance prior to administration of CGRP. There were no significant changes in the vascular resistance related to pregnancy for brain, lung, liver, spleen, stomach, colon, muscle, skin, bladder, kidney, and uterus. However, the vascular resistance was decreased with pregnancy in atria and ventricles of the heart and jejunum.
The administration of CGRP to both pregnant and ovx rats caused widespread change in organ vascular resistance. Vascular resistance to CGRP was significantly lower in all chambers of the heart and stomach of both pregnant and ovx animals. However, in jejunum and kidney the CGRPassociated decreases in vascular resistance occurred only in pregnant but not in ovx rats. In all other organs, CGRPinduced decreases in vascular resistance was noticeable in both pregnant and nonpregnant rats; however, these changes did not attain statistical significance.
The blood flows to various organs of both pregnant and ovx rats are presented in Table 2 . There were no substantial ᭣
FIG. 2. Changes in MAP (A), cardiac output (B)
, and total vascular resistance (C) in ovx rats treated with sesame oil (oil), E 2 (2.5 g/injection s.c., twice daily for 3 days in 0.2 ml of sesame oil), P 4 (2 mg/injection s.c., twice daily for 3 days in 0.2 ml of sesame oil), or E 2 ϩ P 4 , prior to and after single bolus injection of 270 pmol/kg BW CGRP. Values are mean Ϯ SEM for four to six animals in each group. #P Ͻ 0.05 ϭ compared to oil treatment; *P Ͻ 0.05 ϭ compared to before versus after CGRP, within each treatment group. changes in the blood flows to various organs, associated with pregnancy when compared with ovx rats. In both pregnant and ovx rats, injection of CGRP caused significant increases in blood flows to the ventricles of the heart. However, CGRP caused significant increases in blood flow to the jejunum in pregnant but not in ovx animals, indicating CGRP-induced blood flow to the jejunum was increased due to pregnancy.
Effects of CGRP on Systemic Hemodynamics in Ovx Animals Treated with Steroid Hormones
Mean arterial pressure, cardiac output, and total vascular resistance in steroid hormone-treated ovx rats before and after a bolus injection of CGRP are presented in Figure 2 . Significant decreases in MAP occurred in ovx rats treated with the combination of E 2 and P 4 ( Fig. 2A ), but not with either of these hormones alone. Injection of CGRP caused decreases in MAP; however, these effects were significant in ovx rats treated with P 4 or E 2 ϩ P 4 . The cardiac output was higher in ovx rats treated with E 2 and E 2 ϩ P 4 but not with P 4 . In all the ovx rats treated with steroid hormones, the cardiac output was increased upon the administration of CGRP; however, these increases were significant in E 2 -and P 4 -treated rats (Fig. 2B) . Total vascular resistance was significantly lower in only E 2 ϩ P 4 -treated ovx rats. Again in all the ovx rats treated with steroid hormones, the total vascular resistance was decreased upon injection of CGRP, and these effects were significant in E 2 -, P 4 -, and E 2 ϩ P 4 -treated ovx rats (Fig. 2C) . Table 3 shows the effects of bolus administration of CGRP on regional vascular resistance in ovx animals treated with E 2 , P 4 , E 2 ϩ P 4 , or the vehicle only. We initially assessed if steroid hormone treatments induce changes in the vascular resistance to various organs. Both E 2 and E 2 ϩ P 4 treatments caused significant decreases in vascular resistance in the uterus, cervix, and in colon. In addition, E 2 ϩ P 4 caused significant decreases in vascular resistance of jejunum. In all other organs, none of the treatments significantly altered the vascular resistance. Injection of CGRP caused widespread changes in organ vascular resistance in steroid hormone-treated ovx animals. Significant decreases in vascular resistance were observed in brain, ventricles, atria, jejunum, and kidney in ovx rats treated with E 2 , P 4 , or E 2 ϩ P 4 . However, only E 2 treatment caused substantial decreases in CGRP-induced vascular resistance in reproductive organs, uterus, and cervix.
Effects of CGRP on the Regional Vascular Resistance and Blood Flows in Ovx Rats Treated with Steroid Hormones
The effects of CGRP on organ blood flow are presented in Table 4 . Both E 2 and E 2 ϩ P 4 , but not P 4 treatment caused significant increases in blood flow to the uterus and cervix. Administration of CGRP caused generalized increases in blood flow to many organs, both reproductive and nonreproductive, of ovx rats treated with E 2 , P 4 , and E 2 ϩ P 4 ; however, these increases were statistically significant (P Ͻ 0.05) only in ventricles.
DISCUSSION
During the course of gestation, cardiac output, stroke volume, and blood volume increases with a significant fall in arterial blood pressure and systemic vascular resistance to regulate vascular tone and thus maintain homeostasis during pregnancy. In the present study, we observed a significant elevation in cardiac output and significant decreases in MAP and total vascular resistance in pregnant rats compared to nonpregnant ovx rats (Fig. 1) . In addition, for the first time, the data from this report indicate that CGRP, a potent vasodilator, further decreased the MAP and total vascular resistance, which was significant in the pregnant but not in ovx rats, suggesting that vasodilatory sensitivity to CGRP may be increased during pregnancy (Fig. 1) . The data presented herein indicate that CGRP may play a role in mediating the substantially high-output, low-resistance, low-pressure state that is a hallmark of rat gestation.
Steroid hormones, E 2 , or P 4 , either alone or in combination, were injected to ovx rats to assess if these pregnancy-related changes are steroid hormone dependent. The CGRP-induced changes in MAP, total vascular resistance, and cardiac output in E 2 ϩ P 4 -treated rats were similar to that observed in pregnant rats. Therefore, we suggest that the effects of CGRP on vascular resistance and BP during pregnancy are modulated by the increases in these steroid hormones.
We also examined the organ vascular resistance and blood flows to several reproductive and nonreproductive organs prior to and after a bolus injection of CGRP. Major findings include that both pregnancy and steroid hormone treatments to ovx rats caused significant decreases in vascular resistance of jejunum, and these decreases were further enhanced by CGRP. Moreover, in ovx rats treated with E 2 , the vascular resistance was lower in the uterus and cervix with further decreases upon CGRP injection. Therefore, we suggest that mesenteric arterial vascular resistance decreases with pregnancy, and these vessels are more sensitive to CGRP-induced vasodilation during pregnancy and with steroid hormone treatment.
The hypotensive effects of CGRP were much greater in pregnancy and in steroid hormone-treated ovx rats compared with ovx rats (Fig. 1) . These studies are consistent with our previous report [5] in which we demonstrated that CGRP caused greater decreases in MAP in pregnant and in steroid hormone-treated ovx rats compared to vehicle-treated ovx rats. Because the hypotensive effects of CGRP were dose dependent with maximal responses occurring between 180 and 360 pmol CGRP/kg BW, in the present study, we used 270 pmol/kg BW. In both pregnant and steroid hormone-treated rats, the vascular resistance was substantially decreased with CGRP administration, consistent with the mechanisms of action in CGRP-induced vasodilation [15, 16] .
In the present study, we examined if CGRP caused reductions in vascular resistance of various organs. CGRPinduced vascular resistance was substantially lower during pregnancy in the vessels supplying blood to the jejunum, heart, and kidney. Thus, the vasodilatory sensitivity to CGRP was increased with pregnancy in mesenteric, coronary, and renal vasculature. Moreover, the basal resistance (without CGRP injection) was also lower in these vasculatures, indicating that these vessels may play a role in vascular adaptation that occur during pregnancy and that CGRP may be involved in these processes. In pregnant rats, CGRP was ineffective in reducing vascular resistance in the organs associated with reproductive functions and fetal development (uterus, cervix, ovary, and placenta). This could be related to a lack of increased sensitivity to CGRP associated with pregnancy in these organs.
Because the vascular resistance in select organs was decreased with pregnancy and with CGRP administration, we hypothesized that decreases in vascular resistance in these organs may be sex steroid hormone dependent. In the ovx rats treated with E 2 ϩ P 4 , the mesenteric, renal, coronary, and cerebral vascular resistance was substantially lowered by CGRP. CGRP had similar effects on these vessels in ovx animals when treated with either E 2 or P 4 alone, indicating that these hormones may regulate CGRP-induced resistance in these vascular beds. Furthermore, in ovx rats treated with E 2 , the vascular resistance in the uterus and cervix was significantly lower, and these studies are in agreement with several reports in a variety of species [24] [25] [26] [27] [28] [29] . Vascular resistance in these organs was further reduced upon CGRP injection, indicating a role for E 2 in vascular functions of these reproductive organs. Progesterone alone had no significant effects on either basal or CGRP-induced vascular resistance in the uterus and cervix. In steroid hormonetreated animals, the decreases in vascular resistance observed in various organs were accompanied by increases in organ blood flows; however, these increases were significant in the uterus and cervix of E 2 -treated animals. Although ovx rats treated with E 2 ϩ P 4 behaved much like pregnant rats in response to CGRP in cardiac output, MAP, and total vascular resistance ( Figs. 1 and 2 ), they were different from pregnant rats with regard to vascular resistance and blood flow in reproductive organs such as uterus and cervix (Tables 3 and 4 ). This indicates that reproductive organ resistance and flow are more actively regulated by steroid hormones than pregnancy.
A significant increase in blood flow to the ventricles in response to CGRP was a common finding in pregnant and ovx rats whether treated with steroid hormones or vehicle only, further confirming previous reports in male rats [15, 16] . DiPette et al. [15, 16] suggested that the coronary blood flow and vascular resistance were unusually sensitive to CGRP in male rats. Lack of significant increases in blood flow in response to CGRP to brain, kidneys, muscle, and skin in any of the experimental groups in the present study are consistent with other studies [15, 16] . However, significant (P Ͻ 0.05) changes in resistance and blood flow in the mesenteric vessels of jejunum in pregnant rats upon CGRP injection indicate these vessels are more sensitive to CGRP during pregnancy. We, therefore, speculate that pregnancy-related vascular adaptations might involve increases in the sensitivity to CGRP in at least mesenteric and coronary vasculature.
In conclusion, we provide the first comprehensive description of changes in cardiac output, total vascular resistance as well as regional vascular resistance and blood flow to various vascular beds in response to CGRP, in pregnant and ovx rats treated with steroid hormones. We observed that the decreases associated with CGRP-induced total vascular resistance was substantially greater in pregnant and in E 2 ϩ P 4 -treated ovx rats compared to ovx rats. Furthermore, coronary and mesenteric vasculature appeared to be more sensitive to CGRP in both pregnancy and steroid hormone-treated rats. These studies together with our previous studies [3] [4] [5] [6] suggest that CGRP may be involved in vascular adaptations that occur during pregnancy and that steroid hormones may be involved in these mechanisms.
